Illinois General Assembly - Full Text of SB3109
Illinois General Assembly

Previous General Assemblies

Full Text of SB3109  98th General Assembly

SB3109enr 98TH GENERAL ASSEMBLY

  
  
  

 


 
SB3109 EnrolledLRB098 18318 ZMM 53453 b

1    AN ACT concerning regulation.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Illinois Optometric Practice Act of 1987 is
5amended by changing Section 15.1 as follows:
 
6    (225 ILCS 80/15.1)
7    (Section scheduled to be repealed on January 1, 2017)
8    Sec. 15.1. Diagnostic and therapeutic authority.
9    (a) For purposes of the Act, "ocular pharmaceutical agents"
10means topical anesthetics, topical mydriatics, topical
11cycloplegics, topical miotics and mydriatic reversing agents,
12anti-infective agents, anti-allergy agents, anti-glaucoma
13agents (except oral carbonic anhydrase inhibitors, which may be
14prescribed only in a quantity sufficient to provide treatment
15for up to 72 hours), anti-inflammatory agents (except oral
16steroids), over-the-counter agents, analgesic agents, anti-dry
17eye agents, and agents for the treatment of hypotrichosis.
18    (a-3) In addition to ocular pharmaceutical agents that fall
19within the categories set forth in subsection (a) of this
20Section, the Board may add a pharmaceutical agent approved by
21the FDA or class of agents for the purpose of the diagnosis or
22treatment of conditions of the eye and adnexa after
23consideration of the agent's systemic effects, side effects,

 

 

SB3109 Enrolled- 2 -LRB098 18318 ZMM 53453 b

1and the use of the agent within the practice of optometry. The
2Board shall consider requests for additional agents and make
3recommendations within 90 days after the receipt of the
4request.
5    Within 45 days after the Board's recommendation to the
6Department of a pharmaceutical agent or class of agents, the
7Department shall promulgate rules necessary to allow for the
8prescribing or administering of the pharmaceutical agent or
9class of agents under this Act.
10    (a-5) Ocular pharmaceutical agents administered by
11injection may be used only for the treatment of anaphylaxis.
12    (a-10) Oral pharmaceutical agents may be prescribed for a
13child under 5 years of age only in consultation with a
14physician licensed to practice medicine in all its branches.
15    (a-15) The authority to prescribe a Schedule III, IV, or V
16controlled substance shall include only analgesic agents only
17in a quantity sufficient to provide treatment for up to 72
18hours. The prescription of a Schedule II controlled substance
19is prohibited, except for Dihydrocodeinone (Hydrocodone) with
20one or more active, non-narcotic ingredients only in a quantity
21sufficient to provide treatment for up to 72 hours, and only if
22such formulations of Dihydrocodeinone are reclassified as
23Schedule II by federal regulation.
24    (b) A licensed optometrist may remove superficial foreign
25bodies from the human eye and adnexa and may give orders for
26patient care to a nurse licensed to practice under Illinois

 

 

SB3109 Enrolled- 3 -LRB098 18318 ZMM 53453 b

1law.
2    (c) An optometrist's license shall be revoked or suspended
3by the Department upon recommendation of the Board based upon
4either of the following causes:
5        (1) grave or repeated misuse of any ocular
6    pharmaceutical agent; and
7        (2) the use of any agent or procedure in the course of
8    optometric practice by an optometrist not properly
9    authorized under this Act.
10    (d) The Secretary of Financial and Professional Regulation
11shall notify the Director of Public Health as to the categories
12of ocular pharmaceutical agents permitted for use by an
13optometrist. The Director of Public Health shall in turn notify
14every licensed pharmacist in the State of the categories of
15ocular pharmaceutical agents that can be utilized and
16prescribed by an optometrist.
17(Source: P.A. 97-170, eff. 7-22-11.)
 
18    Section 10. The Illinois Controlled Substances Act is
19amended by changing Section 102 as follows:
 
20    (720 ILCS 570/102)  (from Ch. 56 1/2, par. 1102)
21    Sec. 102. Definitions. As used in this Act, unless the
22context otherwise requires:
23    (a) "Addict" means any person who habitually uses any drug,
24chemical, substance or dangerous drug other than alcohol so as

 

 

SB3109 Enrolled- 4 -LRB098 18318 ZMM 53453 b

1to endanger the public morals, health, safety or welfare or who
2is so far addicted to the use of a dangerous drug or controlled
3substance other than alcohol as to have lost the power of self
4control with reference to his or her addiction.
5    (b) "Administer" means the direct application of a
6controlled substance, whether by injection, inhalation,
7ingestion, or any other means, to the body of a patient,
8research subject, or animal (as defined by the Humane
9Euthanasia in Animal Shelters Act) by:
10        (1) a practitioner (or, in his or her presence, by his
11    or her authorized agent),
12        (2) the patient or research subject pursuant to an
13    order, or
14        (3) a euthanasia technician as defined by the Humane
15    Euthanasia in Animal Shelters Act.
16    (c) "Agent" means an authorized person who acts on behalf
17of or at the direction of a manufacturer, distributor,
18dispenser, prescriber, or practitioner. It does not include a
19common or contract carrier, public warehouseman or employee of
20the carrier or warehouseman.
21    (c-1) "Anabolic Steroids" means any drug or hormonal
22substance, chemically and pharmacologically related to
23testosterone (other than estrogens, progestins,
24corticosteroids, and dehydroepiandrosterone), and includes:
25    (i) 3[beta],17-dihydroxy-5a-androstane, 
26    (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, 

 

 

SB3109 Enrolled- 5 -LRB098 18318 ZMM 53453 b

1    (iii) 5[alpha]-androstan-3,17-dione, 
2    (iv) 1-androstenediol (3[beta], 
3        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
4    (v) 1-androstenediol (3[alpha], 
5        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
6    (vi) 4-androstenediol  
7        (3[beta],17[beta]-dihydroxy-androst-4-ene), 
8    (vii) 5-androstenediol  
9        (3[beta],17[beta]-dihydroxy-androst-5-ene), 
10    (viii) 1-androstenedione  
11        ([5alpha]-androst-1-en-3,17-dione), 
12    (ix) 4-androstenedione  
13        (androst-4-en-3,17-dione), 
14    (x) 5-androstenedione  
15        (androst-5-en-3,17-dione), 
16    (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- 
17        hydroxyandrost-4-en-3-one), 
18    (xii) boldenone (17[beta]-hydroxyandrost- 
19        1,4,-diene-3-one), 
20    (xiii) boldione (androsta-1,4- 
21        diene-3,17-dione), 
22    (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 
23        [beta]-hydroxyandrost-4-en-3-one), 
24    (xv) clostebol (4-chloro-17[beta]- 
25        hydroxyandrost-4-en-3-one), 
26    (xvi) dehydrochloromethyltestosterone (4-chloro- 

 

 

SB3109 Enrolled- 6 -LRB098 18318 ZMM 53453 b

1        17[beta]-hydroxy-17[alpha]-methyl- 
2        androst-1,4-dien-3-one), 
3    (xvii) desoxymethyltestosterone 
4    (17[alpha]-methyl-5[alpha] 
5        -androst-2-en-17[beta]-ol)(a.k.a., madol), 
6    (xviii) [delta]1-dihydrotestosterone (a.k.a.  
7        '1-testosterone') (17[beta]-hydroxy- 
8        5[alpha]-androst-1-en-3-one), 
9    (xix) 4-dihydrotestosterone (17[beta]-hydroxy- 
10        androstan-3-one), 
11    (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- 
12        5[alpha]-androstan-3-one), 
13    (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- 
14        hydroxyestr-4-ene), 
15    (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- 
16        1[beta],17[beta]-dihydroxyandrost-4-en-3-one), 
17    (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], 
18        17[beta]-dihydroxyandrost-1,4-dien-3-one), 
19    (xxiv) furazabol (17[alpha]-methyl-17[beta]- 
20        hydroxyandrostano[2,3-c]-furazan), 
21    (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one) 
22    (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- 
23        androst-4-en-3-one), 
24    (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- 
25        dihydroxy-estr-4-en-3-one), 
26    (xxviii) mestanolone (17[alpha]-methyl-17[beta]- 

 

 

SB3109 Enrolled- 7 -LRB098 18318 ZMM 53453 b

1        hydroxy-5-androstan-3-one), 
2    (xxix) mesterolone (1amethyl-17[beta]-hydroxy- 
3        [5a]-androstan-3-one), 
4    (xxx) methandienone (17[alpha]-methyl-17[beta]- 
5        hydroxyandrost-1,4-dien-3-one), 
6    (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- 
7        dihydroxyandrost-5-ene), 
8    (xxxii) methenolone (1-methyl-17[beta]-hydroxy- 
9        5[alpha]-androst-1-en-3-one), 
10    (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- 
11        dihydroxy-5a-androstane), 
12    (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy 
13        -5a-androstane), 
14    (xxxv) 17[alpha]-methyl-3[beta],17[beta]- 
15        dihydroxyandrost-4-ene), 
16    (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- 
17        methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), 
18    (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- 
19        hydroxyestra-4,9(10)-dien-3-one), 
20    (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- 
21        hydroxyestra-4,9-11-trien-3-one), 
22    (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- 
23        hydroxyandrost-4-en-3-one), 
24    (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- 
25        hydroxyestr-4-en-3-one), 
26    (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone  

 

 

SB3109 Enrolled- 8 -LRB098 18318 ZMM 53453 b

1        (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- 
2        androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- 
3        1-testosterone'), 
4    (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), 
5    (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- 
6        dihydroxyestr-4-ene), 
7    (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- 
8        dihydroxyestr-4-ene), 
9    (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- 
10        dihydroxyestr-5-ene), 
11    (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- 
12        dihydroxyestr-5-ene), 
13    (xlvii) 19-nor-4,9(10)-androstadienedione  
14        (estra-4,9(10)-diene-3,17-dione), 
15    (xlviii) 19-nor-4-androstenedione (estr-4- 
16        en-3,17-dione), 
17    (xlix) 19-nor-5-androstenedione (estr-5- 
18        en-3,17-dione), 
19    (l) norbolethone (13[beta], 17a-diethyl-17[beta]- 
20        hydroxygon-4-en-3-one), 
21    (li) norclostebol (4-chloro-17[beta]- 
22        hydroxyestr-4-en-3-one), 
23    (lii) norethandrolone (17[alpha]-ethyl-17[beta]- 
24        hydroxyestr-4-en-3-one), 
25    (liii) normethandrolone (17[alpha]-methyl-17[beta]- 
26        hydroxyestr-4-en-3-one), 

 

 

SB3109 Enrolled- 9 -LRB098 18318 ZMM 53453 b

1    (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- 
2        2-oxa-5[alpha]-androstan-3-one), 
3    (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- 
4        dihydroxyandrost-4-en-3-one), 
5    (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- 
6        17[beta]-hydroxy-(5[alpha]-androstan-3-one), 
7    (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- 
8        (5[alpha]-androst-2-eno[3,2-c]-pyrazole), 
9    (lviii) stenbolone (17[beta]-hydroxy-2-methyl- 
10        (5[alpha]-androst-1-en-3-one), 
11    (lix) testolactone (13-hydroxy-3-oxo-13,17- 
12        secoandrosta-1,4-dien-17-oic 
13        acid lactone), 
14    (lx) testosterone (17[beta]-hydroxyandrost- 
15        4-en-3-one), 
16    (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- 
17        diethyl-17[beta]-hydroxygon- 
18        4,9,11-trien-3-one), 
19    (lxii) trenbolone (17[beta]-hydroxyestr-4,9, 
20        11-trien-3-one). 
21    Any person who is otherwise lawfully in possession of an
22anabolic steroid, or who otherwise lawfully manufactures,
23distributes, dispenses, delivers, or possesses with intent to
24deliver an anabolic steroid, which anabolic steroid is
25expressly intended for and lawfully allowed to be administered
26through implants to livestock or other nonhuman species, and

 

 

SB3109 Enrolled- 10 -LRB098 18318 ZMM 53453 b

1which is approved by the Secretary of Health and Human Services
2for such administration, and which the person intends to
3administer or have administered through such implants, shall
4not be considered to be in unauthorized possession or to
5unlawfully manufacture, distribute, dispense, deliver, or
6possess with intent to deliver such anabolic steroid for
7purposes of this Act.
8    (d) "Administration" means the Drug Enforcement
9Administration, United States Department of Justice, or its
10successor agency.
11    (d-5) "Clinical Director, Prescription Monitoring Program"
12means a Department of Human Services administrative employee
13licensed to either prescribe or dispense controlled substances
14who shall run the clinical aspects of the Department of Human
15Services Prescription Monitoring Program and its Prescription
16Information Library.
17    (d-10) "Compounding" means the preparation and mixing of
18components, excluding flavorings, (1) as the result of a
19prescriber's prescription drug order or initiative based on the
20prescriber-patient-pharmacist relationship in the course of
21professional practice or (2) for the purpose of, or incident
22to, research, teaching, or chemical analysis and not for sale
23or dispensing. "Compounding" includes the preparation of drugs
24or devices in anticipation of receiving prescription drug
25orders based on routine, regularly observed dispensing
26patterns. Commercially available products may be compounded

 

 

SB3109 Enrolled- 11 -LRB098 18318 ZMM 53453 b

1for dispensing to individual patients only if both of the
2following conditions are met: (i) the commercial product is not
3reasonably available from normal distribution channels in a
4timely manner to meet the patient's needs and (ii) the
5prescribing practitioner has requested that the drug be
6compounded.
7    (e) "Control" means to add a drug or other substance, or
8immediate precursor, to a Schedule whether by transfer from
9another Schedule or otherwise.
10    (f) "Controlled Substance" means (i) a drug, substance, or
11immediate precursor in the Schedules of Article II of this Act
12or (ii) a drug or other substance, or immediate precursor,
13designated as a controlled substance by the Department through
14administrative rule. The term does not include distilled
15spirits, wine, malt beverages, or tobacco, as those terms are
16defined or used in the Liquor Control Act of 1934 and the
17Tobacco Products Tax Act of 1995.
18    (f-5) "Controlled substance analog" means a substance:
19        (1) the chemical structure of which is substantially
20    similar to the chemical structure of a controlled substance
21    in Schedule I or II;
22        (2) which has a stimulant, depressant, or
23    hallucinogenic effect on the central nervous system that is
24    substantially similar to or greater than the stimulant,
25    depressant, or hallucinogenic effect on the central
26    nervous system of a controlled substance in Schedule I or

 

 

SB3109 Enrolled- 12 -LRB098 18318 ZMM 53453 b

1    II; or
2        (3) with respect to a particular person, which such
3    person represents or intends to have a stimulant,
4    depressant, or hallucinogenic effect on the central
5    nervous system that is substantially similar to or greater
6    than the stimulant, depressant, or hallucinogenic effect
7    on the central nervous system of a controlled substance in
8    Schedule I or II.
9    (g) "Counterfeit substance" means a controlled substance,
10which, or the container or labeling of which, without
11authorization bears the trademark, trade name, or other
12identifying mark, imprint, number or device, or any likeness
13thereof, of a manufacturer, distributor, or dispenser other
14than the person who in fact manufactured, distributed, or
15dispensed the substance.
16    (h) "Deliver" or "delivery" means the actual, constructive
17or attempted transfer of possession of a controlled substance,
18with or without consideration, whether or not there is an
19agency relationship.
20    (i) "Department" means the Illinois Department of Human
21Services (as successor to the Department of Alcoholism and
22Substance Abuse) or its successor agency.
23    (j) (Blank).
24    (k) "Department of Corrections" means the Department of
25Corrections of the State of Illinois or its successor agency.
26    (l) "Department of Financial and Professional Regulation"

 

 

SB3109 Enrolled- 13 -LRB098 18318 ZMM 53453 b

1means the Department of Financial and Professional Regulation
2of the State of Illinois or its successor agency.
3    (m) "Depressant" means any drug that (i) causes an overall
4depression of central nervous system functions, (ii) causes
5impaired consciousness and awareness, and (iii) can be
6habit-forming or lead to a substance abuse problem, including
7but not limited to alcohol, cannabis and its active principles
8and their analogs, benzodiazepines and their analogs,
9barbiturates and their analogs, opioids (natural and
10synthetic) and their analogs, and chloral hydrate and similar
11sedative hypnotics.
12    (n) (Blank).
13    (o) "Director" means the Director of the Illinois State
14Police or his or her designated agents.
15    (p) "Dispense" means to deliver a controlled substance to
16an ultimate user or research subject by or pursuant to the
17lawful order of a prescriber, including the prescribing,
18administering, packaging, labeling, or compounding necessary
19to prepare the substance for that delivery.
20    (q) "Dispenser" means a practitioner who dispenses.
21    (r) "Distribute" means to deliver, other than by
22administering or dispensing, a controlled substance.
23    (s) "Distributor" means a person who distributes.
24    (t) "Drug" means (1) substances recognized as drugs in the
25official United States Pharmacopoeia, Official Homeopathic
26Pharmacopoeia of the United States, or official National

 

 

SB3109 Enrolled- 14 -LRB098 18318 ZMM 53453 b

1Formulary, or any supplement to any of them; (2) substances
2intended for use in diagnosis, cure, mitigation, treatment, or
3prevention of disease in man or animals; (3) substances (other
4than food) intended to affect the structure of any function of
5the body of man or animals and (4) substances intended for use
6as a component of any article specified in clause (1), (2), or
7(3) of this subsection. It does not include devices or their
8components, parts, or accessories.
9    (t-5) "Euthanasia agency" means an entity certified by the
10Department of Financial and Professional Regulation for the
11purpose of animal euthanasia that holds an animal control
12facility license or animal shelter license under the Animal
13Welfare Act. A euthanasia agency is authorized to purchase,
14store, possess, and utilize Schedule II nonnarcotic and
15Schedule III nonnarcotic drugs for the sole purpose of animal
16euthanasia.
17    (t-10) "Euthanasia drugs" means Schedule II or Schedule III
18substances (nonnarcotic controlled substances) that are used
19by a euthanasia agency for the purpose of animal euthanasia.
20    (u) "Good faith" means the prescribing or dispensing of a
21controlled substance by a practitioner in the regular course of
22professional treatment to or for any person who is under his or
23her treatment for a pathology or condition other than that
24individual's physical or psychological dependence upon or
25addiction to a controlled substance, except as provided herein:
26and application of the term to a pharmacist shall mean the

 

 

SB3109 Enrolled- 15 -LRB098 18318 ZMM 53453 b

1dispensing of a controlled substance pursuant to the
2prescriber's order which in the professional judgment of the
3pharmacist is lawful. The pharmacist shall be guided by
4accepted professional standards including, but not limited to
5the following, in making the judgment:
6        (1) lack of consistency of prescriber-patient
7    relationship,
8        (2) frequency of prescriptions for same drug by one
9    prescriber for large numbers of patients,
10        (3) quantities beyond those normally prescribed,
11        (4) unusual dosages (recognizing that there may be
12    clinical circumstances where more or less than the usual
13    dose may be used legitimately),
14        (5) unusual geographic distances between patient,
15    pharmacist and prescriber,
16        (6) consistent prescribing of habit-forming drugs.
17    (u-0.5) "Hallucinogen" means a drug that causes markedly
18altered sensory perception leading to hallucinations of any
19type.
20    (u-1) "Home infusion services" means services provided by a
21pharmacy in compounding solutions for direct administration to
22a patient in a private residence, long-term care facility, or
23hospice setting by means of parenteral, intravenous,
24intramuscular, subcutaneous, or intraspinal infusion.
25    (u-5) "Illinois State Police" means the State Police of the
26State of Illinois, or its successor agency.

 

 

SB3109 Enrolled- 16 -LRB098 18318 ZMM 53453 b

1    (v) "Immediate precursor" means a substance:
2        (1) which the Department has found to be and by rule
3    designated as being a principal compound used, or produced
4    primarily for use, in the manufacture of a controlled
5    substance;
6        (2) which is an immediate chemical intermediary used or
7    likely to be used in the manufacture of such controlled
8    substance; and
9        (3) the control of which is necessary to prevent,
10    curtail or limit the manufacture of such controlled
11    substance.
12    (w) "Instructional activities" means the acts of teaching,
13educating or instructing by practitioners using controlled
14substances within educational facilities approved by the State
15Board of Education or its successor agency.
16    (x) "Local authorities" means a duly organized State,
17County or Municipal peace unit or police force.
18    (y) "Look-alike substance" means a substance, other than a
19controlled substance which (1) by overall dosage unit
20appearance, including shape, color, size, markings or lack
21thereof, taste, consistency, or any other identifying physical
22characteristic of the substance, would lead a reasonable person
23to believe that the substance is a controlled substance, or (2)
24is expressly or impliedly represented to be a controlled
25substance or is distributed under circumstances which would
26lead a reasonable person to believe that the substance is a

 

 

SB3109 Enrolled- 17 -LRB098 18318 ZMM 53453 b

1controlled substance. For the purpose of determining whether
2the representations made or the circumstances of the
3distribution would lead a reasonable person to believe the
4substance to be a controlled substance under this clause (2) of
5subsection (y), the court or other authority may consider the
6following factors in addition to any other factor that may be
7relevant:
8        (a) statements made by the owner or person in control
9    of the substance concerning its nature, use or effect;
10        (b) statements made to the buyer or recipient that the
11    substance may be resold for profit;
12        (c) whether the substance is packaged in a manner
13    normally used for the illegal distribution of controlled
14    substances;
15        (d) whether the distribution or attempted distribution
16    included an exchange of or demand for money or other
17    property as consideration, and whether the amount of the
18    consideration was substantially greater than the
19    reasonable retail market value of the substance.
20    Clause (1) of this subsection (y) shall not apply to a
21noncontrolled substance in its finished dosage form that was
22initially introduced into commerce prior to the initial
23introduction into commerce of a controlled substance in its
24finished dosage form which it may substantially resemble.
25    Nothing in this subsection (y) prohibits the dispensing or
26distributing of noncontrolled substances by persons authorized

 

 

SB3109 Enrolled- 18 -LRB098 18318 ZMM 53453 b

1to dispense and distribute controlled substances under this
2Act, provided that such action would be deemed to be carried
3out in good faith under subsection (u) if the substances
4involved were controlled substances.
5    Nothing in this subsection (y) or in this Act prohibits the
6manufacture, preparation, propagation, compounding,
7processing, packaging, advertising or distribution of a drug or
8drugs by any person registered pursuant to Section 510 of the
9Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
10    (y-1) "Mail-order pharmacy" means a pharmacy that is
11located in a state of the United States that delivers,
12dispenses or distributes, through the United States Postal
13Service or other common carrier, to Illinois residents, any
14substance which requires a prescription.
15    (z) "Manufacture" means the production, preparation,
16propagation, compounding, conversion or processing of a
17controlled substance other than methamphetamine, either
18directly or indirectly, by extraction from substances of
19natural origin, or independently by means of chemical
20synthesis, or by a combination of extraction and chemical
21synthesis, and includes any packaging or repackaging of the
22substance or labeling of its container, except that this term
23does not include:
24        (1) by an ultimate user, the preparation or compounding
25    of a controlled substance for his or her own use; or
26        (2) by a practitioner, or his or her authorized agent

 

 

SB3109 Enrolled- 19 -LRB098 18318 ZMM 53453 b

1    under his or her supervision, the preparation,
2    compounding, packaging, or labeling of a controlled
3    substance:
4            (a) as an incident to his or her administering or
5        dispensing of a controlled substance in the course of
6        his or her professional practice; or
7            (b) as an incident to lawful research, teaching or
8        chemical analysis and not for sale.
9    (z-1) (Blank).
10    (z-5) "Medication shopping" means the conduct prohibited
11under subsection (a) of Section 314.5 of this Act.
12    (z-10) "Mid-level practitioner" means (i) a physician
13assistant who has been delegated authority to prescribe through
14a written delegation of authority by a physician licensed to
15practice medicine in all of its branches, in accordance with
16Section 7.5 of the Physician Assistant Practice Act of 1987,
17(ii) an advanced practice nurse who has been delegated
18authority to prescribe through a written delegation of
19authority by a physician licensed to practice medicine in all
20of its branches or by a podiatric physician, in accordance with
21Section 65-40 of the Nurse Practice Act, or (iii) an animal
22euthanasia agency.
23    (aa) "Narcotic drug" means any of the following, whether
24produced directly or indirectly by extraction from substances
25of vegetable origin, or independently by means of chemical
26synthesis, or by a combination of extraction and chemical

 

 

SB3109 Enrolled- 20 -LRB098 18318 ZMM 53453 b

1synthesis:
2        (1) opium, opiates, derivatives of opium and opiates,
3    including their isomers, esters, ethers, salts, and salts
4    of isomers, esters, and ethers, whenever the existence of
5    such isomers, esters, ethers, and salts is possible within
6    the specific chemical designation; however the term
7    "narcotic drug" does not include the isoquinoline
8    alkaloids of opium;
9        (2) (blank);
10        (3) opium poppy and poppy straw;
11        (4) coca leaves, except coca leaves and extracts of
12    coca leaves from which substantially all of the cocaine and
13    ecgonine, and their isomers, derivatives and salts, have
14    been removed;
15        (5) cocaine, its salts, optical and geometric isomers,
16    and salts of isomers;
17        (6) ecgonine, its derivatives, their salts, isomers,
18    and salts of isomers;
19        (7) any compound, mixture, or preparation which
20    contains any quantity of any of the substances referred to
21    in subparagraphs (1) through (6).
22    (bb) "Nurse" means a registered nurse licensed under the
23Nurse Practice Act.
24    (cc) (Blank).
25    (dd) "Opiate" means any substance having an addiction
26forming or addiction sustaining liability similar to morphine

 

 

SB3109 Enrolled- 21 -LRB098 18318 ZMM 53453 b

1or being capable of conversion into a drug having addiction
2forming or addiction sustaining liability.
3    (ee) "Opium poppy" means the plant of the species Papaver
4somniferum L., except its seeds.
5    (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
6solution or other liquid form of medication intended for
7administration by mouth, but the term does not include a form
8of medication intended for buccal, sublingual, or transmucosal
9administration.
10    (ff) "Parole and Pardon Board" means the Parole and Pardon
11Board of the State of Illinois or its successor agency.
12    (gg) "Person" means any individual, corporation,
13mail-order pharmacy, government or governmental subdivision or
14agency, business trust, estate, trust, partnership or
15association, or any other entity.
16    (hh) "Pharmacist" means any person who holds a license or
17certificate of registration as a registered pharmacist, a local
18registered pharmacist or a registered assistant pharmacist
19under the Pharmacy Practice Act.
20    (ii) "Pharmacy" means any store, ship or other place in
21which pharmacy is authorized to be practiced under the Pharmacy
22Practice Act.
23    (ii-5) "Pharmacy shopping" means the conduct prohibited
24under subsection (b) of Section 314.5 of this Act.
25    (ii-10) "Physician" (except when the context otherwise
26requires) means a person licensed to practice medicine in all

 

 

SB3109 Enrolled- 22 -LRB098 18318 ZMM 53453 b

1of its branches.
2    (jj) "Poppy straw" means all parts, except the seeds, of
3the opium poppy, after mowing.
4    (kk) "Practitioner" means a physician licensed to practice
5medicine in all its branches, dentist, optometrist, podiatric
6physician, veterinarian, scientific investigator, pharmacist,
7physician assistant, advanced practice nurse, licensed
8practical nurse, registered nurse, hospital, laboratory, or
9pharmacy, or other person licensed, registered, or otherwise
10lawfully permitted by the United States or this State to
11distribute, dispense, conduct research with respect to,
12administer or use in teaching or chemical analysis, a
13controlled substance in the course of professional practice or
14research.
15    (ll) "Pre-printed prescription" means a written
16prescription upon which the designated drug has been indicated
17prior to the time of issuance; the term does not mean a written
18prescription that is individually generated by machine or
19computer in the prescriber's office.
20    (mm) "Prescriber" means a physician licensed to practice
21medicine in all its branches, dentist, optometrist, podiatric
22physician or veterinarian who issues a prescription, a
23physician assistant who issues a prescription for a controlled
24substance in accordance with Section 303.05, a written
25delegation, and a written supervision agreement required under
26Section 7.5 of the Physician Assistant Practice Act of 1987, or

 

 

SB3109 Enrolled- 23 -LRB098 18318 ZMM 53453 b

1an advanced practice nurse with prescriptive authority
2delegated under Section 65-40 of the Nurse Practice Act and in
3accordance with Section 303.05, a written delegation, and a
4written collaborative agreement under Section 65-35 of the
5Nurse Practice Act.
6    (nn) "Prescription" means a written, facsimile, or oral
7order, or an electronic order that complies with applicable
8federal requirements, of a physician licensed to practice
9medicine in all its branches, dentist, podiatric physician or
10veterinarian for any controlled substance, of an optometrist
11for a Schedule II, III, IV, or V controlled substance in
12accordance with Section 15.1 of the Illinois Optometric
13Practice Act of 1987, of a physician assistant for a controlled
14substance in accordance with Section 303.05, a written
15delegation, and a written supervision agreement required under
16Section 7.5 of the Physician Assistant Practice Act of 1987, or
17of an advanced practice nurse with prescriptive authority
18delegated under Section 65-40 of the Nurse Practice Act who
19issues a prescription for a controlled substance in accordance
20with Section 303.05, a written delegation, and a written
21collaborative agreement under Section 65-35 of the Nurse
22Practice Act when required by law.
23    (nn-5) "Prescription Information Library" (PIL) means an
24electronic library that contains reported controlled substance
25data.
26    (nn-10) "Prescription Monitoring Program" (PMP) means the

 

 

SB3109 Enrolled- 24 -LRB098 18318 ZMM 53453 b

1entity that collects, tracks, and stores reported data on
2controlled substances and select drugs pursuant to Section 316.
3    (oo) "Production" or "produce" means manufacture,
4planting, cultivating, growing, or harvesting of a controlled
5substance other than methamphetamine.
6    (pp) "Registrant" means every person who is required to
7register under Section 302 of this Act.
8    (qq) "Registry number" means the number assigned to each
9person authorized to handle controlled substances under the
10laws of the United States and of this State.
11    (qq-5) "Secretary" means, as the context requires, either
12the Secretary of the Department or the Secretary of the
13Department of Financial and Professional Regulation, and the
14Secretary's designated agents.
15    (rr) "State" includes the State of Illinois and any state,
16district, commonwealth, territory, insular possession thereof,
17and any area subject to the legal authority of the United
18States of America.
19    (rr-5) "Stimulant" means any drug that (i) causes an
20overall excitation of central nervous system functions, (ii)
21causes impaired consciousness and awareness, and (iii) can be
22habit-forming or lead to a substance abuse problem, including
23but not limited to amphetamines and their analogs,
24methylphenidate and its analogs, cocaine, and phencyclidine
25and its analogs.
26    (ss) "Ultimate user" means a person who lawfully possesses

 

 

SB3109 Enrolled- 25 -LRB098 18318 ZMM 53453 b

1a controlled substance for his or her own use or for the use of
2a member of his or her household or for administering to an
3animal owned by him or her or by a member of his or her
4household.
5(Source: P.A. 97-334, eff. 1-1-12; 98-214, eff. 8-9-13; revised
611-12-13.)
 
7    Section 99. Effective date. This Act takes effect upon
8becoming law.